• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
    • DeviceTalks
  • Coronavirus: Live updates
Home » FDA: Olympus sold ‘superbug’ scopes without our clearance

FDA: Olympus sold ‘superbug’ scopes without our clearance

March 5, 2015 By Brad Perriello

Olympus sold 'superbug' scopes without FDA approval

The FDA yesterday confirmed that Olympus (TYO:7733) sold the endoscopes implicated in a series of deadly hospital-acquired infections without the safety watchdog’s approval, as more hospitals in California and Connecticut reported infections from the scopes.

Although the fiberoptic Olympus TJF-Q180V duodenoscope “does not currently have a 510(k) clearance,” the FDA said, it’s not advising hospitals to cancel scheduled endoscopic retrograde cholangiopancreatography procedures using that device or 2 other models made by Fujifilm Holdings (TSE:4901) and Hoya Corp.‘s (TYO:7741) Pentax subsidiary.

“Olympus has a pending 510(k) application for this device, and the company continues to market the product while the application is under review. FDA is not taking action against Olympus regarding its device during our review of the application, because, based on the information currently available to the agency, we believe that that removal of the device from the market could lead to an insufficient number of available duodenoscopes to meet the clinical demand in the United States of approximately 500,000 procedures per year,”the FDA said yesterday. “The FDA’s analysis indicates that the reported duodenoscope-associated infections have occurred in patients who have had procedures with duodenoscopes from all 3 manufacturers. At this time, FDA has no evidence that the lack of a 510(k) clearance was associated with the infections.”

FDA spokeswoman Karen Riley told CNN that Olympus put a new design of the TJF-Q180V duodenoscope on the U.S. market in 2010, but the FDA didn’t notice until late 2013 or early 2014 that the company never asked for clearance.

“Why didn’t we notice it? I don’t know,” Riley said. “The company clearly made these modifications to make the device safer, but it seems to be that it wasn’t safer.

“More than 500,000 of these procedures are done every year in the U.S., and the risk of bacterial transmission is actually really very, very low,” she added. “We believe the benefits outweigh the risks.”

In a statement, Olympus told the news channel that it didn’t think needed the FDA’s permission to sell the device but has since applied for it at the agency’s request.

“The emergence of drug-resistant microorganisms is a challenge to the entire health care community. Olympus is working with relevant medical societies and our customers in research of this emerging issue and the development of additional safeguards to prevent infection associated with [duodenoscope procedures],” the company said.

Fujifilm and Pentax won 510(k) clearances for their duodenoscopes, Riley said.

Also yesterday, a 2nd top Los Angeles hospital reported an outbreak of the drug-resistant “superbug” infections and dozens more potential exposures from procedures performed with suspect duodenoscopes.

The notice from Cedars-Sinai Medical Center of 4 such infections and 67 more at-risk patients coincided with a hospital in Hartford, Conn., reporting a similar outbreak involving at least 5 infections and more than 280 potential exposures. The Cedars-Sinai cases, like the larger number of infections and potential exposures reported last month at the UCLA Ronald Reagan Medical Center in Los Angeles, involved a family of germs called carbapenem-resistant Enterobacteriaceae. The bacteria identified on Wednesday in the Hartford Hospital outbreak was a drug-resistant strain of E.coli.

Seven patients were infected with CRE during endoscopies at the UCLA teaching hospital between Oct. 3 and Jan. 28, and 2 died. Officials warned at the time that as many as 179 people may have been exposed to the so-called superbug.

The latest flurry of infections has raised new questions about whether manufacturers’ recommendations for disinfecting duodenoscopes are sufficient to protect patients. The complex design of the instrument – flexible tubes that are threaded down the throat and stomach to the top of the small intestine to drain fluids from blocked pancreatic and bile ducts – may hinder proper cleaning, the FDA has warned.

A senior FDA official said this week that manufacturers’ own tests of disinfection measures they recommend contained flaws that rendered those cleaning procedures unreliable.

Olympus was the maker of the single duodenoscope linked to all 71 patients of concern at Cedars-Sinai, from August 2014 to February 2015, and of 2 suspect scopes tied to 179 potential exposures dating back to October at UCLA. Seven of UCLA patients were confirmed to have been infected and 2 died.

One of the 4 infected Cedars-Sinai patients died from “an underlying disease,” not from the bacteria, as the infection had by then been cleared, the hospital said in a statement.

Hartford Hospital said it found 5 or 6 of its patients had contracted drug-resistant E. coli last year from 2 duodenoscopes used in 281 more procedures, leading doctors to conclude that those additional patients may have been exposed.

Both privately run Cedars-Sinai and UCLA, a public hospital, say they were offering potentially exposed patients free home-testing kits. The 2 facilities also said they have begun using enhanced disinfection procedures, above and beyond the manufacturer recommendations.

Duodenoscopes have been associated with episodic infections for more than a decade. But an increasing number of germs have developed a resistance to antibiotics, making them potentially more dangerous and difficult to treat.

Material from Reuters was used in this report.

Filed Under: Endoscopic, Food & Drug Administration (FDA), Hospital Care, News Well, Regulatory/Compliance Tagged With: Fujifilm, Olympus, Pentax, Ricoh Co.

In case you missed it

  • Learn What Quality Trends to Watch for in 2021
  • HHS could make permanent pandemic-related exemptions for some devices
  • Medtechs can’t set digital strategies aside – DTW Podcast
  • NIH increases PhysIQ contract to $6.6M
  • Senseonics announces $50M from stock offering
  • Protolabs to acquire 3D Hubs for up to $330M
  • TransEnterix receives CE Mark for AI for its robotic surgery system
  • Hillrom to buy Bardy Diagnostics for $375M
  • Philips aquires Capsule Technologies and its medical device data tech
  • Masimo launches iSirona connectivity hub
  • Thermo Fisher to acquire Mesa Biotech
  • MedTech 100 roundup: Finally a dip as industry stays relatively strong
  • These medtech stocks performed the best in 2020
  • Medtronic launches deep brain stim trial for Parkinson’s disease
  • Former FDA commissioner Kessler to help lead Biden’s COVID-19 response
  • Facial swelling and COVID-19 vaccines: 4 facts
  • Here’s what molecular shape can tell you about pharma innovation

RSS From Medical Design & Outsourcing

  • These medtech stocks performed the best in 2020
    While 2020 did not go as planned for anyone, with the twists and turns came opportunities for medtech companies to power forward. Innovations came both as a result of the COVID-19 pandemic and perhaps in spite of the challenges brought on by the virus, highlighted by the increased efforts to produce vaccines and testing while… […]
  • Covestro tests plastics against high-strength hospital disinfectants
    Covestro announced that it recently teamed with disinfectant manufacturer Metrex to test six different Covestro polycarbonate materials against three of Metrex’s products, which are widely used throughout the healthcare industry. As is customary for rapidly assessing the compatibility of plastics to disinfectants, test specimens were pre-strained and underwent several wipe-and-dry cycles with Metrex disinfectants to… […]
  • Integer expands N.Y. battery plant
    Integer announced today that it recently broke ground on an expansion of its Alden, N.Y., facility to accommodate new equipment that will substantially increase the plant’s production capacity for rechargeable Xcellion lithium-ion batteries. The project kicked off in mid-December 2020 and will add both production equipment and a build-out of Integer’s existing facility. The company… […]
  • Diversified Plastics adds high-efficiency vertical presses
    Diversified Plastics (DPI) announced that it recently installed six all-electric vertical injection molding presses. These presses will join DPI’s existing assemblage of vertical presses and provide increased production capacity to meet growing demand from medical device and other original equipment manufacturers (OEMs). DPI uses vertical presses for over-molding and insert-molding, capabilities often required for medical… […]
  • Traco Power expands power supply line for portable medical equipment
    Traco Power announced that it has expanded its TPP 450 high-density 3×5 power supply series. The series now offers Protection Class II models (TPP 450BA-M Open-Frame Models and TPP 450B-M Enclosed with Fan Models), designed for non-stationary requirements where connection to ground is not possible. Key approvals on the original series remain on the expanded… […]
  • Reflow Medical launches low-profile reinforced support catheters
    Reflow Medical today announced it has launched its Reflow Spex Low Profile reinforced support catheters. The Spex LP catheters are designed to provide the lowest profile tip to access and cross the tightest and most complex lesions with a supportive system. They come in 0.014 in. and 0.018 in. sizes and can be combined with… […]
  • Former CDER head Woodcock to lead FDA for now
    FDA veteran Dr. Janet Woodcock has been tapped as interim FDA commissioner by the Biden administration, according to published reports. An article by BioCentury also said that former FDA commissioner David Kessler, who had been mentioned as a possible replacement for current commissioner Stephen Hahn, will be a consultant to the agency but will not… […]
  • What’s next for the FDA and for Stephen Hahn?
    Outgoing FDA commissioner Stephen Hahn says he needs some time to reflect on his future after leading the FDA for a little over a year. It’s hard to blame him. Hahn’s brief tenure at FDA has been rocky, to say the least. (News of his temporary replacement broke on Thursday, when the incoming Biden administration… […]
  • Medicare to cover breakthrough devices
    FDA-designated breakthrough devices will have Medicare coverage the same day they are approved, under a final rule issued this week by the Centers for Medicare and Medicaid Services (CMS). The Medicare Coverage of Innovative Technology (MCIT) rule will provide national Medicare coverage as early as the same day as FDA market authorization for breakthrough devices… […]
  • FDA debuts plan for AI-based Software as a Medical Device
    The FDA today released its first plan to regulate artificial intelligence/machine learning (AI/ML)-based Software as a Medical Device (SaMD). The plan is a response to feedback received from the agency’s April 2019 discussion paper, “Proposed Regulatory Framework for Modifications to Artificial Intelligence/Machine Learning-Based Software as a Medical Device.” It outlines five actions that the FDA… […]
  • EU allows remote audits for medical devices during pandemic
    The European Union has announced that it will temporarily allow remote audits of medical devices and in vitro diagnostics under the new regulations (MDR IVDR), set to go into effect on May 2021 and 2022 respectively. In a document published Monday, the European Commission agreed with industry and notified bodies that the ongoing COVID-19 pandemic… […]

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us

Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS